+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of CREXONT, an extended-release capsule containing Carbidopa and Levodopa, in people with Parkinson disease PD under real-world conditions. This Phase 4 study aims to understand how well CREXONT works in reducing motor symptom fluctuations in participants who are already treated with stable oral Carbidopa-Levodopa regimens. Participants will receive CREXONT extended-release capsules orally, with doses guided by FDA-approved prescribing information. The capsules come in several strengths, and dosing will be adjusted individually to find the best balance between effectiveness and tolerability. The study includes an initial dosing based on prior oral medication and allows optimization throughout the study to meet each participants needs. During the study, participants will complete Parkinsons Disease diaries to track On and Off motor states, and researchers will measure changes in Good On time and Off time by Day 42 compared to baseline. Participants will attend study visits and may receive questionnaires and assessments to monitor their condition and treatment response. The study is open-label, meaning all participants receive CREXONT, and the total participation duration includes baseline and follow-up assessments through Day 42.

Age: 18Years +All GendersPhase 4
27 locations
M

Actively Recruiting

This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.

All AgesAll Genders
402 locations
R

Actively Recruiting

This observational study focuses on people with Parkinsons Disease who are prescribed continuous subcutaneous apomorphine infusion ONAPGO. It aims to collect real-world patient experiences using this infusion in the United States, evaluating how patients manage their treatment and adjust medications over time. The study is a Phase 4, multicenter trial sponsored by Supernus Pharmaceuticals, Inc., designed to better understand patient and caregiver experiences with this therapy. Participants go through several study periods Enrollment Day occurs anytime between their prescription for ONAPGO and starting the infusion a Baseline Period includes in-home education by a Clinical Nurse Navigator followed by Dose Initiation, Titration, and Optimization phases according to prescription. After dose optimization, participants enter a Maintenance Period with ongoing standard care visits by the Clinical Nurse Navigator, ending with a final study or discontinuation visit. Throughout the study, participants are monitored for how long it takes to reach an optimized dose, adjustments to Parkinsons medications, and the number of dose changes needed over approximately 52 to 60 weeks. Researchers also assess patient global health improvement, caregiver burden, healthcare provider burden, infusion usage during maintenance, and safety by tracking adverse events. Participants will have regular interactions with healthcare providers and complete various assessments over the study duration.

Age: 18Years +All Genders
5 locations
R

Actively Recruiting

Researchers are collecting worldwide data on the use of Boston Scientifics Vercise Deep Brain Stimulation DBS System for treating Parkinsons disease. This registry aims to understand how patients respond to the DBS treatment and how it affects their quality of life. The study also evaluates the use of Image Guided Programming IGP and the DBS Illumina 3D feature as tools to help plan patient programming with the Vercise DBS system. Participants receive the Vercise DBS device as part of their Parkinsons disease treatment. The study observes the use of various programming tools, including IGP and the Illumina 3D feature, that assist clinicians in adjusting the DBS device settings to optimize therapy. These programming techniques are monitored and assessed throughout the study. During the registry, participants symptoms and quality of life are tracked and compared to their baseline status before DBS treatment. Data collection includes monitoring symptom improvements and overall well-being up to three years after treatment. This long-term observation helps researchers understand the outcomes and benefits of using the Vercise DBS system for Parkinsons disease.

Age: 18Years +All Genders
87 locations
O

Actively Recruiting

Migraine is a neurological condition marked by moderate to severe headaches, often accompanied by nausea, vomiting, and sensitivity to light and sound. This research evaluates changes in migraine attack severity among adults using oral ubrogepant during migraine attacks. The study will include about 189 adult participants across approximately 15 sites in the US. Participants will take ubrogepant as prescribed by their physicians according to routine clinical practice and local approved guidelines. This observational study involves no experimental treatment changes and follows participants for up to 13 weeks. During this time, participants receive their usual migraine care without additional intervention. Participants will attend regular visits at hospitals or clinics as part of their routine care during the study period. Researchers will monitor the percentage of participants experiencing absence of moderate to severe headache over 24 hours after dosing during the prodrome phase of migraine attacks. The study aims to track real-world effectiveness without adding extra burden to participants.

Age: 18Years +All Genders
3 locations
S

Actively Recruiting

Researchers are evaluating TB006, a monoclonal antibody targeting Galectin-3, in adults with Autism Spectrum Disorder ASD. This study explores whether TB006 can improve core and associated behavioral symptoms by reducing neuroinflammation linked to increased microglial activation. The trial is a Phase 2, multisite, double-blind, placebo-controlled randomized clinical trial with a 14-week treatment phase followed by a 14-week open-label extension for placebo subjects. Participants will be randomly assigned in a 21 ratio to receive either TB006 or a placebo. TB006 is given as an intravenous infusion and is designed to neutralize Galectin-3, which is elevated in individuals with ASD. Those initially receiving placebo will have the opportunity to receive TB006 during the open-label extension. The study measures changes in autism symptoms using various clinical scales over the 14 weeks. During the study, participants will attend regular visits for assessments including Childhood Autism Rating Scores CARS at baseline, week 8, and week 14. Additional evaluations include the NIH Toolbox, Clinical Global Impression Scale, Social Responsiveness Scale, and behavioral checklists. Caregivers will also provide input through questionnaires. Safety monitoring includes vital signs and laboratory tests. Overall participation spans the double-blind phase and potential open-label extension, totaling up to 28 weeks.

Age: 18Years - 35YearsAll GendersPhase 2
2 locations